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Co-infections: 
potentially lethal and 
unexplored in COVID-19
Respiratory viral infections predispose 
patients to co-infections and these 
lead to increased disease severity 
and mortality. Most fatalities in the 
1918 influenza outbreak were due 
to subsequent bacterial infection, 
particularly with Streptococcus 
pneumoniae.1 Poor outcomes in the 
2009 H1N1 influenza pandemic 
were also associated with bacterial 
co-infections, although few studies 
captured these data.2 
Despite the proven importance 
of co-infections in the severity 
of respiratory diseases, they are 
understudied during large outbreaks 
of respiratory infections. Zhou 
and colleagues3 showed that in 
the current coronavirus disease 
2019 (COVID-19) pandemic, 50% 
of patients with COVID-19 who 
have died had secondary bacterial 
infections, and Chen and colleagues4 
have recorded both bacterial and 
fungal co-infections. Although 
71% of the admitted patients with 
COVID-19 received antibiotic drugs, 
no information is available on the 
antimicrobial sensitivities of the 
organisms that were identified, or on 
the type and duration of antimicrobial 
treatment. Chronic obstructive 
pulmonary disease (COPD) is a risk 
factor for severe COVID-19 disease and 
many patients with COPD will have 
underlying chronic bacterial infections 
before severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
infection, but this important 
information is not being reported. 
More data on co-infections are 
urgently required to establish their 
importance in COVID-19 severity and 
mortality.
Diagnosing co-infections is complex. 
The organism itself might be carried by 
the patient before the viral infection, 
might be part of an underlying 
chronic infection, or might be picked 
up nosocomially. In the UK, National 
Institute for Health and Care Excellence 
(NICE) treatment guidance for 
severe acquired pneumonia is broad-
spectrum antibiotic co-amoxiclav 
plus a macrolide to cover atypical 
organisms. Currently, antibiotic 
use is high (74·5%) among patients 
with COVID-19 who are admitted 
to intensive care units, rendering 
culture-based microbiological testing 
less sensitive. Patients with COVID-19 
are kept on invasive mechanical 
ventilation for a long time (mean 
9·1 days [SD 5·5]), increasing chances 
of hospital and ventilator acquired 
infections. Hence, early diagnosis of 
co-infection is required, preferably 
using methods capable of detecting 
a broad range of potential pathogens 
and antimicrobial resistances, with 
subsequent monitoring for infection 
development. To accurately diagnose 
and study co-infection in COVID-19, 
patients should be recruited on 
admission to intensive care units and 
sampled longitudinally throughout 
the disease course using culture-
independent techniques capable 
of identifying complex mixed 
infections without previous target 
selection, such as whole-genome 
metagenomics.5 Such a study would 
provide valuable surveillance data on 
the pathogens causing co-infections 
and antimicrobial resistance in the 
intensive care setting, thereby helping 
inform antibiotic prescribing policy.
Rapid characterisation of co-
infection is essential in the manage-
ment and treatment of the most 
severe COVID-19 cases, could help 
to save lives, and will improve 
antimicrobial stewardship throughout 
the course of the pandemic.
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